Comprehensive Market Access Strategy includes Stakeholder Engagement, Clinical and Economic Evidence Generation, Value Proposition Development, Pricing & Reimbursement, and Market Readiness Assessments that are Patient-Centric at their core.

Developing and delivering evidence-based value propositions that include Planning and Gap Analysis, Stakeholder-centric Aligned Messaging, Patient Centered Metrics (including PROs, QoL and RWE approaches), Economic Model Assessment, and Continuous HEOR Strategy Optimization throughout the peri launch period and marketed lifecycle of an asset.

Primary assessment of pricing point ranges that can deliver a competitive entry into a specific market. Work done assesses existing analogs, alternate therapies and existing reimbursement structures/policies to address the market entry. Assessment of coding, coverage, and reimbursement, whether for the actual product, setting of care and/or physician/provider reimbursement (i.e. DRG, APC, CPT, HCPCS, J-codes, etc.) are included where applicable.

Planning and implementation of global early access programs (EAP, NPS, CUP). Leveraging understanding of global regulations that make it possible to introduce FDA or EU approved treatments into global markets. Build and execution of these programs leveraging all functions necessary with the organization.

Ensuring organizationally aligned stakeholder targeted messaging. Understanding, anticipating and reacting to stakeholder decision making processes. Ensuring and driving collaborative message development across Market Access, Medical Affairs, Clinical Development, and Commercial teams to ensure aligned value messages, evidence requirements, and stakeholder engagement plans.

Our firm offers the design and delivery of tailored training programs that build and develop essential team skills in all the categories that are illustrated above.

Provide insight and guidance on forging positive relationships with and partner from advocacy organizations that will positively impact their constituents. Bridge the gap between Advocacy Organizational Strategy and Manufacturer Commercial Launch/Growth Strategy. Broker and foster positive and productive interorganizational relationships and collaborative strategies.

Provide surveillance of evolving landscape issues that can impact governmental and commercial coverage and reimbursement policy development. Ensure that evidence generation strategy is aligned to where policy decision making is headed. Ensure that developing pricing strategies align to policy shifts. Connect policy developments to advocacy strategy changes.